Dr Nicky Lawrence

Oncology Research Fellow and Lecturer
NH&MRC Clinical Trials Centre


Map

Selected grants

2016

  • Optimising cooperative group cancer clinical trials in the era of molecularly targeted treatments; Lawrence N; Auckland Academic Health Alliance/Goldman Sachs New Zealand Foundation Clinical Fellowship in Cancer Medicine.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Hayne, D., Stockler, M., McCombie, S., Lawrence, N., Martin, A., Sengupta, S., Davis, I. (2017). BCG�+�Mitomycin trial for high-risk non-muscle-invasive bladder cancer: progress report and lessons learned. BJU International, 119, 55-57. [More Information]
  • Lawrence, N., Hinder, V., Murray, M., Macapagal, J., Thompson, P., Sharples, K., Findlay, M. (2017). Transient elevation in serum carcinoembryonic antigen while on adjuvant chemotherapy for colon cancer: Is this of prognostic importance? Asia-Pacific Journal of Clinical Oncology, 13(2), e124-e131. [More Information]
  • Templeton, A., Knox, J., Lin, X., Simantov, R., Xie, W., Lawrence, N., Broom, R., Fay, A., Rini, B., et al (2016). Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. European Urology, 70(2), 358-364. [More Information]
  • Lawrence, N., Martin, A., Toner, G., Stockler, M., Buizen, L., Thomson, D., Gebski, V., Friedlander, M., Yeung, A., Wong, N., Grimison, P., et al (2016). Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Annals of Oncology, 27(12), 2302-2303. [More Information]
  • Lawrence, N., Salkeld, G., Stockler, M., Karikios, D. (2016). Valuing the benefits of new anticancer drugs. Medical Journal of Australia, 204(11), 403-405.
  • Kroeger, N., Pantuck, A., Wells, J., Lawrence, N., Broom, R., Kim, J., Srinivas, S., Yim, J., Bjarnason, G., Templeton, A., et al (2015). Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. European Urology, 68(3), 506-515. [More Information]
  • Mitchell, N., Fong, P., Broom, R. (2015). Clinical experience with sunitinib dose escalation in metastatic renal cell carcinoma. Asia-Pacific Journal of Clinical Oncology, 11(3), e1-5. [More Information]

Conferences

  • Mitchell, N., Porter, D. (2014). Does endocrine therapy in mucinous and tubular breast cancer improve outcome? American Society of Clinical Oncology (ASCO) 2014, Chicago, USA.
  • Broom, R., Dranitsaris, G., Fraser-Browne, C., Thompson, K., Duffey, S., Wilson, G., Oei, P., Zwi, J., McKeage, M., Mitchell, N., et al (2014). Dovitinib in first-line metastatic renal cell carcinoma and correlation of efficacy with tumor gene status: A phase II clinical trial. American Society of Clinical Oncology (ASCO) 2014, Chicago, USA.
  • Broom, R., Duffey, S., Fraser-Browne, C., Wilson, G., Thompson, K., Hanning, F., Mitchell, N., Zwi, J., McKeage, M., Dranitsaris, G., et al (2014). Dovitinib in first-line renal cell carcinoma: An investigation into tumour gene status and correlation with efficacy: A phase II clinical trial. 2014 Genitourinary Cancers Symposium, San Francisco, California, USA.
  • Mitchell, N., Hinder, V., Murray, M., Macapagal, J., Thompson, P., Sharples, K., Findlay, M. (2014). Transient increase in serum CEA while on adjuvant chemotherapy for colon cancer: Is this of prognostic importance? 2014 Gastrointestinal Cancers Symposium, San Francisco, California, USA.

2017

  • Hayne, D., Stockler, M., McCombie, S., Lawrence, N., Martin, A., Sengupta, S., Davis, I. (2017). BCG�+�Mitomycin trial for high-risk non-muscle-invasive bladder cancer: progress report and lessons learned. BJU International, 119, 55-57. [More Information]
  • Lawrence, N., Hinder, V., Murray, M., Macapagal, J., Thompson, P., Sharples, K., Findlay, M. (2017). Transient elevation in serum carcinoembryonic antigen while on adjuvant chemotherapy for colon cancer: Is this of prognostic importance? Asia-Pacific Journal of Clinical Oncology, 13(2), e124-e131. [More Information]

2016

  • Templeton, A., Knox, J., Lin, X., Simantov, R., Xie, W., Lawrence, N., Broom, R., Fay, A., Rini, B., et al (2016). Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. European Urology, 70(2), 358-364. [More Information]
  • Lawrence, N., Martin, A., Toner, G., Stockler, M., Buizen, L., Thomson, D., Gebski, V., Friedlander, M., Yeung, A., Wong, N., Grimison, P., et al (2016). Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Annals of Oncology, 27(12), 2302-2303. [More Information]
  • Lawrence, N., Salkeld, G., Stockler, M., Karikios, D. (2016). Valuing the benefits of new anticancer drugs. Medical Journal of Australia, 204(11), 403-405.

2015

  • Kroeger, N., Pantuck, A., Wells, J., Lawrence, N., Broom, R., Kim, J., Srinivas, S., Yim, J., Bjarnason, G., Templeton, A., et al (2015). Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. European Urology, 68(3), 506-515. [More Information]
  • Mitchell, N., Fong, P., Broom, R. (2015). Clinical experience with sunitinib dose escalation in metastatic renal cell carcinoma. Asia-Pacific Journal of Clinical Oncology, 11(3), e1-5. [More Information]

2014

  • Mitchell, N., Porter, D. (2014). Does endocrine therapy in mucinous and tubular breast cancer improve outcome? American Society of Clinical Oncology (ASCO) 2014, Chicago, USA.
  • Broom, R., Dranitsaris, G., Fraser-Browne, C., Thompson, K., Duffey, S., Wilson, G., Oei, P., Zwi, J., McKeage, M., Mitchell, N., et al (2014). Dovitinib in first-line metastatic renal cell carcinoma and correlation of efficacy with tumor gene status: A phase II clinical trial. American Society of Clinical Oncology (ASCO) 2014, Chicago, USA.
  • Broom, R., Duffey, S., Fraser-Browne, C., Wilson, G., Thompson, K., Hanning, F., Mitchell, N., Zwi, J., McKeage, M., Dranitsaris, G., et al (2014). Dovitinib in first-line renal cell carcinoma: An investigation into tumour gene status and correlation with efficacy: A phase II clinical trial. 2014 Genitourinary Cancers Symposium, San Francisco, California, USA.
  • Mitchell, N., Hinder, V., Murray, M., Macapagal, J., Thompson, P., Sharples, K., Findlay, M. (2014). Transient increase in serum CEA while on adjuvant chemotherapy for colon cancer: Is this of prognostic importance? 2014 Gastrointestinal Cancers Symposium, San Francisco, California, USA.

To update your profile click here. For support on your academic profile contact .